

David R Gandara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8035265/publications.pdf>

Version: 2024-02-01

99
papers

11,378
citations

76326

40
h-index

40979

93
g-index

100
all docs

100
docs citations

100
times ranked

12697
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Nonâ€“Small Cell Lung Cancer: Results From the Randomized OAK Trial. <i>Clinical Lung Cancer</i> , 2022, 23, 21-33.	2.6	12
2	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. <i>British Journal of Cancer</i> , 2022, 126, 514-520.	6.4	19
3	Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2022, 22, 407.	2.6	9
4	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Nonâ€“Small-Cell Lung Cancer Previously Treated With Immunotherapyâ€“Lung-MAP S1800A. <i>Journal of Clinical Oncology</i> , 2022, 40, 2295-2307.	1.6	84
5	A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous nonâ€“small cell lung cancer bearing pathogenic <i>STK11</i> genomic alterations (SWOG S1900C.) <i>Tj ETQq1 1 01784314 rBT /Ov</i>	1.6	6
6	Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9014-9014.	1.6	6
7	Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced nonâ€“small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9004-9004.	1.6	6
8	Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).. <i>Journal of Clinical Oncology</i> , 2022, 40, 6543-6543.	1.6	0
9	The 27-gene IO score is associated with molecular features and response to immune checkpoint inhibitors (ICI) in patients with gastric cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4058-4058.	1.6	0
10	Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKIâ€“Treated Patients with <i>EGFR</i> -Mutant NSCLC (SWOG S1403). <i>Clinical Cancer Research</i> , 2022, 28, 3752-3760.	7.0	18
11	SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). <i>Clinical Lung Cancer</i> , 2021, 22, 178-186.	2.6	6
12	Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2021, 16, 140-150.	1.1	95
13	Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. <i>Clinical Lung Cancer</i> , 2021, 22, 67-70.	2.6	33
14	Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 56-62.	27.6	99
15	Fast progression in nonâ€“small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. , 2021, 9, e001882.		12
16	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). <i>JCO Oncology Practice</i> , 2021, 17, e1821-e1829.	2.9	4
17	Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 335-341.	2.3	7
18	Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). <i>Clinical Lung Cancer</i> , 2021, 22, 541-548.	2.6	8

#	ARTICLE	IF	CITATIONS
19	ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy. <i>JCO Precision Oncology</i> , 2021, 5, 827-838.	3.0	36
20	Novel Clinical Trial Designs in Pursuit of Precision Oncology: Lung-MAP As a Model. <i>Clinical Lung Cancer</i> , 2021, 22, 153-155.	2.6	1
21	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)., 2021, 9, e002973.		26
22	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1165-1178.	3.1	20
23	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1368.	7.1	57
24	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	1.1	274
25	CT Volumetry and Basic Texture Analysis as Surrogate Markers in Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 225-231.	2.6	4
26	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq0 0 0 rgBT (Overlap 10 Tf 50	10.7	68
27	Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. <i>Cancer</i> , 2020, 126, 3219-3228.	4.1	106
28	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1611-1623.	1.1	43
29	Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies. <i>Clinical Lung Cancer</i> , 2019, 20, 451-460.e5.	2.6	8
30	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1289-1301.	2.3	29
31	SWOG S1400C (NCT02154490)â€”A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alterationâ€”Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1853-1859.	1.1	58
32	SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathwayâ€”Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1847-1852.	1.1	62
33	SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1839-1846.	1.1	53
34	EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade. <i>Clinical Lung Cancer</i> , 2019, 20, e238-e241.	2.6	21
35	Biomarker Testing for Patients With Advanced Non-small Cell Lung Cancer: Real-World Issues and Tough Choices. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 531-542.	3.8	210
36	Challenges and approaches to implementing master/basket trials in oncology. <i>Blood Advances</i> , 2019, 3, 2237-2243.	5.2	11

#	ARTICLE	IF	CITATIONS
37	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 25-36.	1.1	68
38	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. <i>Clinical Cancer Research</i> , 2018, 24, 3292-3298.	7.0	41
39	Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). <i>Journal of the National Cancer Institute</i> , 2018, 110, 734-742.	6.3	32
40	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 165-183.	1.1	134
41	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. <i>Clinical Lung Cancer</i> , 2018, 19, 331-339.	2.6	15
42	A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. <i>British Journal of Haematology</i> , 2018, 180, 445-448.	2.5	4
43	An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. <i>Clinical Lung Cancer</i> , 2018, 19, 42-50.	2.6	6
44	Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC. <i>Clinical Lung Cancer</i> , 2018, 19, 35-41.	2.6	9
45	Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, 84-92.	2.6	7
46	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1906-1918.	1.1	88
47	Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1156-1170.	1.1	195
48	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268.	1.1	515
49	Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. <i>Nature Medicine</i> , 2018, 24, 1441-1448.	30.7	936
50	CT perfusion imaging of lung cancer: benefit of motion correction for blood flow estimates. <i>European Radiology</i> , 2018, 28, 5069-5075.	4.5	11
51	Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 281-285.	2.6	35
52	Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy. <i>Cancer Treatment and Research Communications</i> , 2017, 10, 21-26.	1.7	17
53	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	1.1	40
54	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 556-566.	1.1	40

#	ARTICLE	IF	CITATIONS
55	Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 1-4.	2.6	14
56	Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma. <i>Carcinogenesis</i> , 2017, 38, bgw205.	2.8	56
57	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet</i> , The, 2017, 389, 255-265.	13.7	3,872
58	Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry. <i>Lung Cancer</i> , 2017, 112, 165-168.	2.0	29
59	Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 477-490.	1.1	30
60	Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 60-67.	2.6	6
61	Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 43-49.	2.6	31
62	Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3717-3718.	1.6	13
63	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2066-2081.	1.1	49
64	Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. <i>Journal of Clinical Oncology</i> , 2016, 34, 3992-3999.	1.6	87
65	Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival. <i>Clinical Proteomics</i> , 2016, 13, 31.	2.1	39
66	Clinicopathologic Features of Advanced Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1411-1422.	1.1	101
67	Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer. <i>Cancer Prevention Research</i> , 2016, 9, 317-323.	1.5	15
68	Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 300.	7.1	4
69	Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. <i>Metabolites</i> , 2015, 5, 192-210.	2.9	69
70	Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. <i>PLoS ONE</i> , 2015, 10, e0134346.	2.5	72
71	Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma. <i>Cancer Prevention Research</i> , 2015, 8, 410-418.	1.5	79
72	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5439-5444.	7.0	104

#	ARTICLE	IF	CITATIONS
73	Lung Master Protocol (Lung-MAP)â€”A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. <i>Clinical Cancer Research</i> , 2015, 21, 1514-1524.	7.0	205
74	Targeting of MEK in lung cancer therapeutics. <i>Lancet Respiratory Medicine</i> , 2015, 3, 319-327.	10.7	40
75	Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 897-907.	2.3	27
76	Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1716-1723.	2.5	58
77	Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2463-2470.	1.6	69
78	Acquired Resistance to Targeted Therapies Against Oncogene-Driven Nonâ€”Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications. <i>Clinical Lung Cancer</i> , 2014, 15, 1-6.	2.6	79
79	Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysis. <i>Lung Cancer</i> , 2014, 85, 264-269.	2.0	68
80	Genotyping and Genomic Profiling of Nonâ€”Small-Cell Lung Cancer: Implications for Current and Future Therapies. <i>Journal of Clinical Oncology</i> , 2013, 31, 1039-1049.	1.6	438
81	A five-arm, open-label, phase I/IIb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3023-3023.	1.6	10
82	SWOG S0533: A pilot trial of cisplatin (C)/etoposide (E)/radiotherapy (RT) followed by consolidation docetaxel (D) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7018-7018.	1.6	7
83	SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7083-7083.	1.6	5
84	A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with <i>ALK</i>-positive (<i>ALK</i>+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7599-7599.	1.6	3
85	A multicenter randomized phase III trial of customized chemotherapy versus standard of care for first-line treatment of elderly patients with advanced non-small cell lung cancer (EPIC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS7619-TPS7619.	1.6	0
86	Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1933-1938.	1.1	54
87	Evolving Treatment Algorithms for Advanced Nonâ€”Small-Cell Lung Cancer: 2009 Looking Toward 2012. <i>Clinical Lung Cancer</i> , 2009, 10, 392-394.	2.6	22
88	Integration of Novel Therapeutics into Combined Modality Therapy of Locally Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5057s-5062s.	7.0	41
89	Therapeutic Strategies for Combined-Modality Therapy of Locally Advanced-Stage Nonâ€”Small-Cell Lung Cancer: Rationale for Consolidation Docetaxel Therapy. <i>Clinical Lung Cancer</i> , 2005, 7, S93-S97.	2.6	3
90	Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia. <i>Seminars in Oncology</i> , 2002, 29, 102-109.	2.2	56

#	ARTICLE	IF	CITATIONS
91	Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 3210-3218.	1.6	1,072
92	Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment. <i>Journal of Clinical Oncology</i> , 2001, 19, 1728-1733.	1.6	522
93	Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2001, 92, 146-152.	4.1	41
94	Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. <i>Cancer</i> , 1999, 86, 684-688.	4.1	43
95	Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. <i>Investigational New Drugs</i> , 1998, 16, 69-75.	2.6	25
96	Promising new agents in the treatment of non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 37, 385-393.	2.3	43
97	Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base. <i>Cancer</i> , 1993, 72, 1184-1191.	4.1	42
98	Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer. <i>Cancer</i> , 1991, 68, 948-958.	4.1	33
99	Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 24, 135-6.	2.3	4